Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway

Abstract

Atorvastatin is proven to ameliorate cardiac hypertrophy induced by chronic intermittent hypoxia (CIH). However, little is known about the mechanism by which atorvastatin modulates CIH-induced cardiac hypertrophy, and whether specific hypertrophyrelated microRNAs are involved in the modulation. MiR-31 plays key roles in the development of cardiac hypertrophy induced by ischemia/hypoxia. This study examined whether miR-31 was involved in the protective role of atorvastatin against CIH-induced myocardial hypertrophy. H9c2 cells were subjected to 8-h intermittent hypoxia per day in the presence or absence of atorvastatin for 5 days. The size of cardiomyocytes, and the expression of caspase 3 and miR-31 were determined by Western blotting and RT-PCR, respectively. MiR-31 mimic or Ro 31-8220, a specific inhibitor of protein kinase C epsilon (PKCε), was used to determine the role of miR-31 in the anti-hypertrophic effect of atorvastatin on cardiomyocytes. PKCε in the cardiomyocytes with miR-31 upregulation or downregulation was detected using RT-PCR and Western blotting. The results showed that CIH induced obvious enlargement of cardiomyocytes, which was paralleled with increased atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and slow/beta cardiac myosin heavy-chain (MYH7) mRNA levels. All these changes were reversed by the treatment with atorvastatin. Meanwhile, miR-31 was increased by CIH in vitro. Of note, the atorvastatin pretreatment significantly increased the mRNA and protein expression of PKCe and decreased that of miR-31. Moreover, overexpression of miR-31 abolished the anti-hypertrophic effect of atorvastatin on cardiomyocytes. Upregulation and downregulation of miR-31 respectively decreased and increased the mRNA and protein expression of PKCε. These results suggest that atorvastatin provides the cardioprotective effects against CIH probably via up-regulating PKCε and down-regulating miR-31.

Keywords

atorvastatin / chronic intermittent hypoxia / myocardial remodeling / miR-31 / protein kinase C epsilon

References

[1] PeppardPE, YoungT, PaltaM, et al.. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med, 2000, 342(19): 1378-1384

[2] GottliebDJ, YenokyanG, NewmanAB, et al.. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation, 2010, 122(4): 352-360

[3] YaggiHK, ConcatoJ, KernanWN, et al.. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med, 2005, 353(19): 2034-2041

[4] MinicM, GrantonJT, RyanCM. Sleep disordered breathing in group 1 pulmonary arterial hypertension. J Clin Sleep Med, 2014, 10(3): 277-283

[5] XieS, DengY, PanYY, et al.. Melatonin protects against chronic intermittent hypoxia-induced cardiac hypertrophy by modulating autophagy through the 5' adenosine monophosphate-activated protein kinase pathway. Biochem Biophs Res Commun, 2015, 464(4): 975-981

[6] MaronDJ, FazioS, LintonMF. Current perspectives on statins. Circulation, 2000, 101(2): 207-213

[7] DietrichA, KalwaH, GudermannT. TRPC channels in vascular cell function. Thromb Haemost, 2010, 103(2): 262-270

[8] TotosonP, FhayliW, FauryG. Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Exp Biol Med, 2013, 238(2): 223-232

[9] ChenY, YuS, ZhangN, et al.. Atorvastatin prevents angiotensin II-induced myocardial hypertrophy in vitro via CCAAT/enhancer-binding protein p. Biochem Biophs Res Commun, 2017, 486(2): 423-430

[10] YuanX, DengY, GuoX, et al.. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: Partly involvement of TLR-4/MYD88 pathway. Biochem Biophs Res Commun, 2014, 446(1): 292-297

[11] RybinVO, SteinbergSF. Protein kinase C isoform expression and regulation in the developing rat heart. Circ Res, 1994, 74(2): 299-309

[12] PaulK, BallNA, DornG 2, et al.. Left ventricular stretch stimulates angiotensin II-mediated phosphatidylinositol hydrolysis and protein kinase C epsilon isoform translocation in adult guinea pig hearts. Circ Res, 1997, 81(5): 643-650

[13] DekkerLV, ParkerP J. Protein kinase C~a question of specificity. Trends Biochem Sci, 1994, 19(2): 73-77

[14] DisatnikMH, BuraggiG, Mochly-RosenD. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res, 1994, 210(2): 287-297

[15] McCarthyJ, LochnerA, OpieLH, et al.. PKCE promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3P inhibition. J Cell Physiol, 2011, 226(9): 2457-2468

[16] TaoL, BeiY, ZhouY, et al.. Non-coding RNAs in cardiac regeneration. Oncotarget, 2015, 6(40): 42613-42622

[17] GrecoCM, CondorelliG. Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nat Rev Cardiol, 2015, 12(8): 488-497

[18] SilvaAQ, SchreihoferAM. Altered sympathetic reflexes and vascular reactivity in rats after exposure to chronic intermittent hypoxia. J Physiol, 2011, 589(6): 1463-1476

[19] JoshiSR, DhagiaV, GairheS, et al.. MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol, 2016, 311(3): H689-H698

[20] PingP, ZhangJ, ZhengYT, et al.. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ Res, 1999, 85(6): 542-550

[21] WangY, MenM, YangW, et al.. MiR-31 downregulation protects against cardiac ischemia/ reperfusion injury by targeting protein kinase C epsilon (PKCe) directly. Cell Physiol Biochem, 2015, 36(1): 179-90

[22] DuanHY, LiuDM, QianP, et al.. Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure. Genet Mol Res, 2015, 14(4): 15739-15748

[23] KlusonovaP, RehakovaL, BorchertG, et al.. Chronic intermittent hypoxia induces llbeta-hydroxysteroid dehydrogenase in rat heart. Endocrinology, 2009, 150(9): 4270-4277

[24] ScheubelRJ, BartlingB, SimmA, et al.. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium. JAm Coll Cardiol, 2002, 39(3): 481-488

[25] AnLP, AnSK, WeiXH, et al.. Atorvastatin improves cardiac function of rats with chronic cardiac failure via inhibiting Racl/P47phox/P67phox-mediated ROS release. Eur Rev Med Pharmacol Sci, 2015, 19(20): 3940-3946

[26] LuJ, LiuF, LiuD, et al.. Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/ osteoprotegerin system in spontaneous hypertension rats. Exp Biol Med, 2016, 241(11): 1237-1249

[27] FarhKK, GrimsonA, JanC, et al.. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science, 2005, 310(5755): 1817-1821

[28] BrownlowN, PikeT, CrosslandV, et al.. Regulation of the cytokinesis cleavage furrow by PKCE. Biochem Soc Trans, 2014, 6(42): 1534-1537

[29] JinZQ, KarlinerJS. Low dose N, N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCepsilon dependent mechanism. Cardiovasc Res, 2006, 71(4): 725-734